With support from Jazz Pharmaceuticals, the grant will fund a SU2C Catalyst® Research Team led by Dr. Grohar; the team will investigate new, targeted treatments for patients 10 years and older with Ewing sarcoma.

CHOP researchers have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant.

Through collaboration with research partners, patients, foundations, and community members, we are working to defeat childhood brain cancer and find better treatments for current patients. Read about recent milestones we’ve hit to accelerate pediatric brain tumor research.

Read this case study about integrating precision medicine into the standard of care for children with thyroid cancer.

Nearly 50 faculty, staff and trainees from the Division of Hematology and Division of Oncology at Children’s Hospital of Philadelphia attended the 64th Annual American Hematology Society (ASH) Meeting in New Orleans, Louisiana.

Two researchers from Children’s Hospital of Philadelphia (CHOP) were recently selected by the health and science news outlet STAT as 2022 Wunderkinds, an award that celebrates the next generation of scientific superstars who are making significant contributions to biomedical research.

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

CHOP researchers found that a series of “liquid biopsies” could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma.

Researchers from Children’s Hospital of Philadelphia (CHOP) have found that economically disadvantaged children treated with CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) fair just as well as children from more socioeconomically advantaged backgrounds.

CHOP researchers have identified a protein on the surface of multiple pediatric brain tumors that they can target using immunotherapy in preclinical models.